Could tricyclic antidepressants be more effective at treating depression in patients with Parkinson's disease? They have been used since the 1950s for treatment of depression, but in recent years, selective serotonin reuptake inhibitors (SSRIs) have become the predominant form of therapy. New research is suggesting that SSRIs may not be the best antidepressant option for our patients with Parkinson's. The lead author of this research, Dr. Matthew Menza, professor of psychiatry and neurology, and interim chair of psychiatry at the Robert Wood Johnson Medical School, speaks with host Dr. Larry Kaskel about the potential implications of his study on how we care for our Parkinson's patients who are also suffering from depression. Dr. Menza also explores a few other relevant issues: the reticence, among many of those with Parkinson's, to speak with their physician about depression, and the concurrent reluctance, among many in the medical community, to recognize and treat their patients' vulnerability to depression.
Are Older Drugs 'In' Again for Depression in Parkinson’s?

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Could tricyclic antidepressants be more effective at treating depression in patients with Parkinson's disease? They have been used since the 1950s for treatment of depression, but in recent years, selective serotonin reuptake inhibitors (SSRIs) have become the predominant form of therapy. New research is suggesting that SSRIs may not be the best antidepressant option for our patients with Parkinson's. The lead author of this research, Dr. Matthew Menza, professor of psychiatry and neurology, and interim chair of psychiatry at the Robert Wood Johnson Medical School, speaks with host Dr. Larry Kaskel about the potential implications of his study on how we care for our Parkinson's patients who are also suffering from depression. Dr. Menza also explores a few other relevant issues: the reticence, among many of those with Parkinson's, to speak with their physician about depression, and the concurrent reluctance, among many in the medical community, to recognize and treat their patients' vulnerability to depression.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Evolving Our View of the Coagulation Cascade and Stroke Management
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
Maximizing Adherence and Persistence via Patient Engagement
Love Story: Lipid Education for Women’s Heart Health
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
Navigating Myasthenia Gravis in Adolescents and Young Adults
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?